.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01X_OtherAntineoplasticAgents.L01XL07_IdecabtageneVicleucel.IdecabtageneVicleucel .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01X_OtherAntineoplasticAgents.L01XL07_IdecabtageneVicleucel.IdecabtageneVicleucel| name: | IdecabtageneVicleucel |
| ATC code: | L01XL07 | route: | intravenous |
| n-compartments | 0 |
Idecabtagene vicleucel is a B-cell maturation antigen (BCMA)-directed genetically modified autologous chimeric antigen receptor (CAR) T-cell therapy used for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy. It is currently FDA and EMA approved.
As a CAR T-cell therapy, idecabtagene vicleucel does not have traditional pharmacokinetic parameters (absorption, distribution, metabolism, elimination) associated with small molecule or typical biologic drugs. Instead, expansion and persistence of transduced CAR T-cells are measured in peripheral blood. Published sources do not provide classic PK parameters such as volume of distribution or clearance.